A significant decrease in ALT levels in the blood and a downregulation in hepatic senescence marker gene p16INK4a, which drives the phenotype of NAFLD33 suggest the possibility of suppressing the progression of NAFLD. The gene discussed is CDKN2A; the disease is metabolic dysfunction-associated steatotic liver disease.